Drug Database
Back to search

Netherlands· NL-6941583fad91

Nalbufine HCl Orpha 10 mg/ml oplossing voor injectie

A nalbuphine product containing nalbufine hydrochloride, registered in Netherlands by Orpha Devel Handels-und Vertriebs GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC N02AF02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNalbufine HCl Orpha 10 mg/ml oplossin…ATCN02AF02REGISTER NO.NL-6941583fad91PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nalbufine hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nalbuphine is registered in 11 of 19 countries.

Countries holding a registration under ATC N02AF02 (nalbuphine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search nalbuphine products by name

Nalbuphine · ATC N02AF02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NALBUFINE HYDROCHLORIDE
Manufacturer
Orpha Devel Handels-und Vertriebs GmbH
Country
Netherlands (NL)
ATC code
N02AF02
ATC class
Nalbuphine
Defined daily dose
80 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    30852

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

148 interactions on record for nalbuphine.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nalbuphine against other medicinesHow interaction checks work

Nalbuphine · interactions on record

148 records

  • 18 severe
  • 98 moderate
  • 32 info

Most severe, free to view

  • AlvimopanA06AH02severe
  • OpiumA07DA02severe
  • ChlorphenesinD01AE07severe
  • ChlorphenesinG01AX21severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nalbuphine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nalbuphine products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Austria · Nalbuphin Amomed, Nubain
  • Czechia · Nalbuphin Orpha
  • Germany · Nalpain, Nubain
  • France · Nalbuphine Renaudin, Nalbuphine Serb
  • Greece · Nalpain
  • Hungary · Nalpain
  • Poland · Nalpain

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c91aaedb-ce64-45c3-bc7a-83f80d44cb95
GET /v1/drugs/c91aaedb-ce64-45c3-bc7a-83f80d44cb95?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": null,
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h30852_smpc.pdf",
  "strength": null,
  "atc_label": "Nalbufine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg30852",
  "excipients": [
    "CITROENZUUR 0-WATER (E 330)",
    "NATRIUMCHLORIDE",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "WATER, GEZUIVERD",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "NALBUFINE HYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h30852.pdf",
  "authorised_at": "2006/03/23",
  "procedure_number": "NL/H/0983/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "30852",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about nalbuphine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console